Sequence: KLULKLULKULKAULKLUGC + cRGDfC
| Experiment Id | EXP000811 |
|---|---|
| Paper | Structure-activity relationship study of Aib-containing amphipathic helical peptide-cyclic RGD conju |
| Peptide | PI |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.2–2.5 µM (assay-dependent) |
| Rna Concentration | 10–25 nM (assay-dependent) |
| Mixing Ratio | 20–100 (peptide:siRNA molar); complexation up to 1000 tested for PV/PVI |
| Formulation Format | electrostatic peptide/siRNA complex |
| Formulation Components | Aib-containing amphipathic helical peptide–cRGDfC conjugate; siRNA |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549 (uptake); A549-Luc (knockdown) |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown (luciferase) |
| Output Value | |
| Output Units | |
| Output Notes | A549-Luc luciferase knockdown observed; tested peptide/siRNA molar ratios 20, 50, 100 (1.0 µM/10 nM at ratio 100; 0.5 µM/10 nM at ratio 50; 0.2 µM/10 nM at ratio 20). Uptake shown in A549 cells by confocal microscopy with AlexaFluor488-siRNA (2.5 µM peptide / 25 nM siRNA, 6 h). |
| Toxicity Notes | |
| Curation Notes |